General Information of the Compound
| Compound ID |
CP0062701
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
DANAZOL
Show/Hide
|
||||||||||||||||||
| Synonyms |
(1R,3aS,3bR,10aR,10bS,12aS)-1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol
(1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4(8),5,9-trien-17-ol
1-Ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol
17-alpha-2,4-Pregnadien-20-yno(2,3-d)isoxazol-17-ol
17-alpha-Pregn-4-en-20-yno(2,3-d)isoxazol-17-ol
17-alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol
17.Alpha.-Pregna-2, {4-dien-20-yno[2,3-d]isoxazol-17-ol}
17alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol
Alphapharm Brand of Danazol
Anatrol
Antigen Brand of Danazol
Chronogyn
Cyclomen
Danatrol
Danazant
Danazol
Danazol (JAN/USP/INN)
Danazol [USAN:BAN:INN:JAN];[1,2]oxazolo[4',5':2,3]-17alpha-pregn-4-en-20-yn-17-ol
Danazol-ratiopharm
Danazole
Danazolum
Danazolum [INN-Latin]
Danocrine
Danocrine (TN)
Danogen
Danokrin
Danol
Danoval
Danzol
Kendrick Brand of Danazol
Ladogal
Norciden
Panacrine
Ratiopharm Brand of Danazol
Sanofi Brand of Danazol
Sanofi Synthelabo Brand ofDanazol
Sanofi Winthrop Brand of Danazol
WIN 17,757
WIN 17757
WIN-17757
Win 17, 757
Winobanin
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C22H27NO2
|
||||||||||||||||||
| Molecular Weight |
337.463
|
||||||||||||||||||
| Canonical SMILES |
C[C@]12CC[C@H]3[C@@H](CCC4=Cc5oncc5C[C@]34C)[C@@H]1CC[C@@]2(O)C#C
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C22H27NO2/c1-4-22(24)10-8-18-16-6-5-15-11-19-14(13-23-25-19)12-20(15,2)17(16)7-9-21(18,22)3/h1,11,13,16-18,24H,5-10,12H2,2-3H3/t16-,17+,18+,20+,21+,22+/m1/s1
Show/Hide
|
||||||||||||||||||
| InChIKey |
POZRVZJJTULAOH-LHZXLZLDSA-N
|
||||||||||||||||||
| CAS |
17230-88-5
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
| DrugBank ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT04542, Bile salt export pump
Protein ID: PT00905, Cytochrome P450 2C9
Protein ID: PT00886, Estrogen receptor
Protein ID: PT00967, Glucocorticoid receptor
Clinical Information about the Compound